Metabolism:肥胖儿童循环中微小RNA的改变可以反应成年糖尿病的风险!

2017-10-21 xing.T MedSci原创

该研究的结果可以更好地理解循环中miRNAs尤其是miR-486、miR-146b和miR-15b在预测肥胖儿童将来T2DM风险中的作用。

儿童肥胖会增加成人2型糖尿病(T2DM)的易感性,循环血浆中微小RNA(miRNAs)已被提议作为潜在的诊断标志物,和他们可能会加速T2DM的进展。近日,代谢性疾病领域权威杂志Metabolism-Clinical and Experimental上发表了一篇研究文章,研究人员的目的是利用循环中miRNAs来预测肥胖儿童成年后T2DM风险的可能性。

研究人员对肥胖儿童进行了miRNA高通量测序,以筛选相关的循环miRNAs。研究人员对肥胖儿童和T2DM成人患者靶向miRNA的表达模式进行了进一步的探索,为了探讨这些miRNAs对糖尿病发生发展潜在的作用,研究人员检测了候选miRNAs对前脂肪细胞增殖、胰岛β细胞胰岛素分泌和骨骼肌细胞葡萄糖摄取的影响。

研究人员发现三个miRNAs(miR-486、miR-146b、miR-15b)循环中的表达增加在肥胖儿童和成人糖尿病患者最为显著,因此这些miRNAs被作为候选对象进行进一步调查。在这3个miRNAs中, miR-486参与了促进前脂肪细胞增殖和肌管葡萄糖耐受不良,miR-146b和miR-15b可以抑制高浓度葡萄糖诱导的胰岛素分泌,这些机制都导致了肥胖和T2DM的病理过程。

该研究的结果可以更好地理解循环中miRNAs尤其是miR-486、miR-146b和miR-15b在预测肥胖儿童将来T2DM风险中的作用。

原始出处:

Xianwei Cui,et al. Change in circulating microRNA profile of obese children indicates future risk of adult diabetes.Metabolism-Clinical and Experimental.2017. http://dx.doi.org/10.1016/j.metabol.2017.09.006

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1717210, encodeId=fe091e172107b, content=<a href='/topic/show?id=4b0a8189ed5' target=_blank style='color:#2F92EE;'>#肥胖儿童#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81897, encryptionId=4b0a8189ed5, topicName=肥胖儿童)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad9f32366344, createdName=minlingfeng, createdTime=Thu Feb 01 11:29:00 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887744, encodeId=3fcf188e74442, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Sep 19 16:29:00 CST 2018, time=2018-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896169, encodeId=b0bd1896169f0, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Aug 09 11:29:00 CST 2018, time=2018-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399486, encodeId=a488139948643, content=<a href='/topic/show?id=c7fc5058804' target=_blank style='color:#2F92EE;'>#微小RNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50588, encryptionId=c7fc5058804, topicName=微小RNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21e42213106, createdName=bshuang, createdTime=Mon Oct 23 11:29:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577177, encodeId=ab1015e7177c0, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Mon Oct 23 11:29:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597981, encodeId=d3cb159e98133, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Mon Oct 23 11:29:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604212, encodeId=224816042126e, content=<a href='/topic/show?id=a2df4684e9a' target=_blank style='color:#2F92EE;'>#小RNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46847, encryptionId=a2df4684e9a, topicName=小RNA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9119152195, createdName=花花1372, createdTime=Mon Oct 23 11:29:00 CST 2017, time=2017-10-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1717210, encodeId=fe091e172107b, content=<a href='/topic/show?id=4b0a8189ed5' target=_blank style='color:#2F92EE;'>#肥胖儿童#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81897, encryptionId=4b0a8189ed5, topicName=肥胖儿童)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad9f32366344, createdName=minlingfeng, createdTime=Thu Feb 01 11:29:00 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887744, encodeId=3fcf188e74442, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Sep 19 16:29:00 CST 2018, time=2018-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896169, encodeId=b0bd1896169f0, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Aug 09 11:29:00 CST 2018, time=2018-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399486, encodeId=a488139948643, content=<a href='/topic/show?id=c7fc5058804' target=_blank style='color:#2F92EE;'>#微小RNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50588, encryptionId=c7fc5058804, topicName=微小RNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21e42213106, createdName=bshuang, createdTime=Mon Oct 23 11:29:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577177, encodeId=ab1015e7177c0, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Mon Oct 23 11:29:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597981, encodeId=d3cb159e98133, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Mon Oct 23 11:29:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604212, encodeId=224816042126e, content=<a href='/topic/show?id=a2df4684e9a' target=_blank style='color:#2F92EE;'>#小RNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46847, encryptionId=a2df4684e9a, topicName=小RNA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9119152195, createdName=花花1372, createdTime=Mon Oct 23 11:29:00 CST 2017, time=2017-10-23, status=1, ipAttribution=)]
    2018-09-19 guojianrong
  3. [GetPortalCommentsPageByObjectIdResponse(id=1717210, encodeId=fe091e172107b, content=<a href='/topic/show?id=4b0a8189ed5' target=_blank style='color:#2F92EE;'>#肥胖儿童#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81897, encryptionId=4b0a8189ed5, topicName=肥胖儿童)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad9f32366344, createdName=minlingfeng, createdTime=Thu Feb 01 11:29:00 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887744, encodeId=3fcf188e74442, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Sep 19 16:29:00 CST 2018, time=2018-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896169, encodeId=b0bd1896169f0, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Aug 09 11:29:00 CST 2018, time=2018-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399486, encodeId=a488139948643, content=<a href='/topic/show?id=c7fc5058804' target=_blank style='color:#2F92EE;'>#微小RNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50588, encryptionId=c7fc5058804, topicName=微小RNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21e42213106, createdName=bshuang, createdTime=Mon Oct 23 11:29:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577177, encodeId=ab1015e7177c0, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Mon Oct 23 11:29:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597981, encodeId=d3cb159e98133, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Mon Oct 23 11:29:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604212, encodeId=224816042126e, content=<a href='/topic/show?id=a2df4684e9a' target=_blank style='color:#2F92EE;'>#小RNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46847, encryptionId=a2df4684e9a, topicName=小RNA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9119152195, createdName=花花1372, createdTime=Mon Oct 23 11:29:00 CST 2017, time=2017-10-23, status=1, ipAttribution=)]
    2018-08-09 一闲
  4. [GetPortalCommentsPageByObjectIdResponse(id=1717210, encodeId=fe091e172107b, content=<a href='/topic/show?id=4b0a8189ed5' target=_blank style='color:#2F92EE;'>#肥胖儿童#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81897, encryptionId=4b0a8189ed5, topicName=肥胖儿童)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad9f32366344, createdName=minlingfeng, createdTime=Thu Feb 01 11:29:00 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887744, encodeId=3fcf188e74442, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Sep 19 16:29:00 CST 2018, time=2018-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896169, encodeId=b0bd1896169f0, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Aug 09 11:29:00 CST 2018, time=2018-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399486, encodeId=a488139948643, content=<a href='/topic/show?id=c7fc5058804' target=_blank style='color:#2F92EE;'>#微小RNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50588, encryptionId=c7fc5058804, topicName=微小RNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21e42213106, createdName=bshuang, createdTime=Mon Oct 23 11:29:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577177, encodeId=ab1015e7177c0, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Mon Oct 23 11:29:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597981, encodeId=d3cb159e98133, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Mon Oct 23 11:29:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604212, encodeId=224816042126e, content=<a href='/topic/show?id=a2df4684e9a' target=_blank style='color:#2F92EE;'>#小RNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46847, encryptionId=a2df4684e9a, topicName=小RNA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9119152195, createdName=花花1372, createdTime=Mon Oct 23 11:29:00 CST 2017, time=2017-10-23, status=1, ipAttribution=)]
    2017-10-23 bshuang
  5. [GetPortalCommentsPageByObjectIdResponse(id=1717210, encodeId=fe091e172107b, content=<a href='/topic/show?id=4b0a8189ed5' target=_blank style='color:#2F92EE;'>#肥胖儿童#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81897, encryptionId=4b0a8189ed5, topicName=肥胖儿童)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad9f32366344, createdName=minlingfeng, createdTime=Thu Feb 01 11:29:00 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887744, encodeId=3fcf188e74442, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Sep 19 16:29:00 CST 2018, time=2018-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896169, encodeId=b0bd1896169f0, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Aug 09 11:29:00 CST 2018, time=2018-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399486, encodeId=a488139948643, content=<a href='/topic/show?id=c7fc5058804' target=_blank style='color:#2F92EE;'>#微小RNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50588, encryptionId=c7fc5058804, topicName=微小RNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21e42213106, createdName=bshuang, createdTime=Mon Oct 23 11:29:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577177, encodeId=ab1015e7177c0, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Mon Oct 23 11:29:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597981, encodeId=d3cb159e98133, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Mon Oct 23 11:29:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604212, encodeId=224816042126e, content=<a href='/topic/show?id=a2df4684e9a' target=_blank style='color:#2F92EE;'>#小RNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46847, encryptionId=a2df4684e9a, topicName=小RNA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9119152195, createdName=花花1372, createdTime=Mon Oct 23 11:29:00 CST 2017, time=2017-10-23, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1717210, encodeId=fe091e172107b, content=<a href='/topic/show?id=4b0a8189ed5' target=_blank style='color:#2F92EE;'>#肥胖儿童#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81897, encryptionId=4b0a8189ed5, topicName=肥胖儿童)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad9f32366344, createdName=minlingfeng, createdTime=Thu Feb 01 11:29:00 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887744, encodeId=3fcf188e74442, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Sep 19 16:29:00 CST 2018, time=2018-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896169, encodeId=b0bd1896169f0, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Aug 09 11:29:00 CST 2018, time=2018-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399486, encodeId=a488139948643, content=<a href='/topic/show?id=c7fc5058804' target=_blank style='color:#2F92EE;'>#微小RNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50588, encryptionId=c7fc5058804, topicName=微小RNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21e42213106, createdName=bshuang, createdTime=Mon Oct 23 11:29:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577177, encodeId=ab1015e7177c0, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Mon Oct 23 11:29:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597981, encodeId=d3cb159e98133, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Mon Oct 23 11:29:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604212, encodeId=224816042126e, content=<a href='/topic/show?id=a2df4684e9a' target=_blank style='color:#2F92EE;'>#小RNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46847, encryptionId=a2df4684e9a, topicName=小RNA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9119152195, createdName=花花1372, createdTime=Mon Oct 23 11:29:00 CST 2017, time=2017-10-23, status=1, ipAttribution=)]
    2017-10-23 闆锋旦
  7. [GetPortalCommentsPageByObjectIdResponse(id=1717210, encodeId=fe091e172107b, content=<a href='/topic/show?id=4b0a8189ed5' target=_blank style='color:#2F92EE;'>#肥胖儿童#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81897, encryptionId=4b0a8189ed5, topicName=肥胖儿童)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad9f32366344, createdName=minlingfeng, createdTime=Thu Feb 01 11:29:00 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887744, encodeId=3fcf188e74442, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Sep 19 16:29:00 CST 2018, time=2018-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896169, encodeId=b0bd1896169f0, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Aug 09 11:29:00 CST 2018, time=2018-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399486, encodeId=a488139948643, content=<a href='/topic/show?id=c7fc5058804' target=_blank style='color:#2F92EE;'>#微小RNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50588, encryptionId=c7fc5058804, topicName=微小RNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21e42213106, createdName=bshuang, createdTime=Mon Oct 23 11:29:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577177, encodeId=ab1015e7177c0, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Mon Oct 23 11:29:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597981, encodeId=d3cb159e98133, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Mon Oct 23 11:29:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604212, encodeId=224816042126e, content=<a href='/topic/show?id=a2df4684e9a' target=_blank style='color:#2F92EE;'>#小RNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46847, encryptionId=a2df4684e9a, topicName=小RNA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9119152195, createdName=花花1372, createdTime=Mon Oct 23 11:29:00 CST 2017, time=2017-10-23, status=1, ipAttribution=)]
    2017-10-23 花花1372

相关资讯

美疾控中心:美国40%癌症病例与超重肥胖有关!

美国疾病控制和预防中心日前发布报告说,美国目前40%的癌症病例与体重超重和肥胖相关,超重和肥胖问题正在威胁美国过去20年取得的抗癌进展。

Cell Metab:研究揭示肥胖是如何一步步诱发了乳腺癌!

肥胖导致细胞因子释放到影响乳腺癌细胞代谢的血液中,从而使它们更具侵略性。来自亥姆霍兹中心慕尼黑,慕尼黑工业大学(TUM)和海德堡大学医院的科学家在细胞代谢中报道了这一点。该小组已经能够通过抗体治疗来阻止这种机制。

世卫组织公布《终止儿童肥胖实施计划》

记者近日从世界卫生组织驻华代表处获悉,世卫组织和伦敦帝国理工学院共同完成的一项研究结果显示,过去40年,世界各地5岁~19岁的肥胖儿童和青少年人数增加了10倍。依照目前的趋势,到2022年,儿童和青少年肥胖人数将超过中度或重度体重不足人数。据悉该研究是有史以来参与人数最多的一次流行病学调查

Cell Res: 间歇性节食有助于对抗肥胖

在长达16周的间歇性禁食中,不需要计算卡路里,有助于对抗肥胖和其他代谢紊乱。根据Kyoung-Han Kim和Yun Hye Kim在Cell Research杂志上的一项研究,这样的禁食在仅仅六周后就已经显示出了好处。小鼠间歇性禁食有助于启动动物的新陈代谢,通过产生热量来燃烧脂肪。这个研究小组由加拿大安大略的生病儿童医院的Hoon Ki Sung主持。研究表明,我们不健康的饮食习惯和久坐不动的生

Diabetes Obes Metab:肥胖成人:达格列净每天一次+艾塞那肽每周一次效果如何?

超重和肥胖在全球高度流行,分别影响39%和13%的成年人,并且与2型糖尿病、心血管疾病、非酒精性脂肪性肝病和肌肉骨骼疾病相关。2017年9月,发表在《Diabetes Obes Metab》的一项由瑞典科学家进行的研究,考察了在无糖尿病的肥胖成人中,达格列净每天一次+艾塞那肽每周一次对体重、血糖和血压的影响。

Acta Psychiatrica Scandinavica:中国人群研究:肥胖与BDNF对双相障碍患者子女大脑结构的影响

脑源性神经营养因子(Brain Derived Neurotrophic Factor)是神经营养因子家族中重要的成员之一,在神经重塑机制中扮演重要角色。情感障碍的发生可能与神经脑网络对外界刺激的适应异常有关,有效的治疗方案可加强神经可塑性,使得神经脑网络结构对外界刺激有更为适宜的调整,因此,BDNF在双相障碍的发病机制中起重要作用。此外,BDNF参与糖和能量代谢的调节,以及参与肥胖的形成。